Acquired hemolytic anemia

The VA rates Acquired hemolytic anemia under Diagnostic Code 7723 at 0%, 10%, 30%, 60%, 100%. The minimum 0% rating requires: Asymptomatic. The maximum 100% rating requires: Requiring a bone marrow transplant or continuous intravenous or immunosuppressive therapy (e.g., prednisone, Cytoxan, azathioprine, or rituximab).

The VA rates Acquired hemolytic anemia under Diagnostic Code (DC) 7723, governed by 38 CFR 38 CFR § 4.117. The diagnostic code establishes the specific rating tiers and severity criteria the VA examiner applies.

A 0% rating requires: Asymptomatic. A 100% rating requires: Requiring a bone marrow transplant or continuous intravenous or immunosuppressive therapy (e.g., prednisone, Cytoxan, azathioprine, or rituximab). The difference typically reflects the frequency, severity, or functional impact of the condition as documented in medical records and C&P examination findings.

Veterans rated for Acquired hemolytic anemia may qualify for TDIU if the condition — alone or in combination with other service-connected disabilities — prevents substantially gainful employment. A single disability rated at 60% or higher (or multiple disabilities combining to 70%, with one at 40%) can support a TDIU claim under 38 CFR § 4.16.

Service connection for Acquired hemolytic anemia requires three elements: (1) a current diagnosis of the condition, (2) an in-service event, injury, or disease, and (3) a medical nexus linking the current diagnosis to that in-service occurrence. A nexus letter from a treating or independent medical examiner is the most reliable nexus evidence.

A Compensation & Pension (C&P) exam for Acquired hemolytic anemia uses a Disability Benefits Questionnaire (DBQ) specific to the body system involved. The examiner documents the frequency, severity, and functional impact of your symptoms. Bring all relevant treatment records and be prepared to describe your worst-day symptoms — the examiner rates your condition based on the full clinical picture, not a single visit.